Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $16,472.95 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 25,343 shares of the stock in a transaction on Friday, April 4th. The stock was sold at an average price of $0.65, for a total transaction of $16,472.95. Following the transaction, the chief executive officer now owns 191,374 shares in the company, valued at approximately $124,393.10. This trade represents a 11.69 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Accelerate Diagnostics Price Performance

Shares of Accelerate Diagnostics stock opened at $0.60 on Thursday. Accelerate Diagnostics, Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.09. The firm has a fifty day moving average price of $1.03 and a two-hundred day moving average price of $1.36. The company has a market cap of $15.05 million, a PE ratio of -0.21 and a beta of 0.46.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, March 20th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $3.00 million. Analysts expect that Accelerate Diagnostics, Inc. will post -2.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Accelerate Diagnostics

A number of hedge funds have recently made changes to their positions in AXDX. Renaissance Technologies LLC raised its stake in shares of Accelerate Diagnostics by 160.6% in the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after buying an additional 65,984 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Accelerate Diagnostics in the 4th quarter valued at $27,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Accelerate Diagnostics in the 3rd quarter valued at $34,000. Finally, Geode Capital Management LLC raised its stake in shares of Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after buying an additional 8,777 shares in the last quarter. Institutional investors and hedge funds own 17.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th. StockNews.com assumed coverage on shares of Accelerate Diagnostics in a report on Thursday. They set a “hold” rating for the company.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.